{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-053843","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.752070+00:00","generated_at":"2026-06-18T22:11:15.110936+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atea reports Q4 2022 net loss of $34.4M; provides clinical updates on COVID-19, HCV, and dengue programs","bullets":["Net loss of $34.4M ($0.41 loss per share) in Q4 2022 vs net income of $117.1M in Q4 2021; full year 2022 net loss $115.9M.","Revenue $0 in Q4 and full year 2022 vs $192.2M and $351.4M in 2021 due to end of Roche collaboration.","Cash and marketable securities $646.7M at Dec 31, 2022, down from $764.4M at Dec 31, 2021.","Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 continues enrollment; interim analysis expected 2H23.","Dengue program deprioritized; Phase 2 HCV combination trial to start enrollment in 2Q23 with initial results by 4Q23."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-053843","json":"https://secwatch.observer/filing/0001193125-23-053843.json","markdown":"https://secwatch.observer/filing/0001193125-23-053843.md","text":"https://secwatch.observer/filing/0001193125-23-053843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523053843/0001193125-23-053843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523053843/d462845d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:11:15.110936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf20fa4f2aa2a73e0c179e6b0372774d761f9ff5","claim":"Atea Pharmaceuticals, Inc. reported financial results for Q4 and Full Year 2022.","evidence_excerpt":"Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523053843/0001193125-23-053843-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 and Full Year 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}